Low-dose Molecular Breast Imaging: Comparison of Breast Cancer Detection Rate at Initial Screening and Two-year Follow-up
Low-dose Molecular Breast Imaging: Comparison of Breast Cancer Detection Rate at Initial Screening and Two-year Follow-up
The purpose of this research is to evaluate whether repeating a screening Molecular Breast
 Imaging (MBI) study two years after an initial screening MBI study further improves breast
 cancer detection in women with dense breast tissue.
Inclusion Criteria:

 - Past prior screening mammogram within the previous 11-24 months interpreted as
 heterogeneously dense or extremely dense and negative or benign [Breast Imaging Reporting
 and Data System (BI-RADS) Category 1 or 2]

 Exclusion Criteria:

 Subjects will be excluded if they:

 -  Are unable to understand and sign the consent form

 -  Are pregnant or lactating

 -  Are physically unable to sit upright and still for 40 minutes

 -  Have self-reported signs or symptoms that may suggest breast cancer (palpable mass,
 bloody nipple discharge, axillary mass, etc.)

 -  Have had needle biopsy within 3 months, or breast surgery or radiation within 1 year
 prior to the study

 -  Are currently receiving chemotherapy or tamoxifen, raloxifene, or an aromatase
 inhibitor for adjuvant therapy or chemoprevention

 -  Have undergone bilateral mastectomy

 -  Have had a prior MBI within 20 months of scheduled study MBI.